| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:22.)
© 2001 American Heart Association, Inc.
Original Contributions |
Treatment of Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin
Results of the TOPAS Trial
From Universitätsklinikum Essen (H.C.D.); Universität Münster (E.B.R.); Universität Dresden (R.von K.); Klinikum Fulda (H.D.L.); Krankenhaus Köln-Merheim (H.B.); Wenckebach-Krankenhaus, Berlin (H.L.); Universitätsklinikum Mannheim (M.H.); Universität Regensburg (D.W.); and Novartis Pharma, Nürnberg (M.G., J.B., G.W.) (Germany).
Correspondence to Professor Dr H.C. Diener, Neurologische Klinik und Poliklinik, Universitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, Germany. E-mail h.diener{at}uni-essen.de
Background and Purpose—To study the safety and efficacy of the low-molecular-weight heparin certoparin, we performed a randomized, double-blind, dose-finding multicenter trial in patients with acute ischemic stroke (Therapy of Patients With Acute Stroke [TOPAS]).
Methods—We randomized
404 patients to 4 treatment groups within 12 hours of stroke onset:
3000 U anti–factor Xa (aXa) certoparin once daily (treatment group 1);
3000 U aXa twice daily (group 2); 5000 U aXa twice daily (group 3); and
8000 U aXa twice daily (group 4). The primary efficacy variable was
the proportion of patients reaching a favorable functional outcome
(Barthel Index 
90 points) at 3 months. CT was performed at trial
entry, after 7 days, and on clinical
deterioration.
Results—The proportion
of patients with Barthel Index 90 was not different between treatment
arms (61.5%, 60.8%, 63.3%, and 56.3% in the 4 groups, respectively;
intent-to-treat population). European Stroke Scale scores improved in
all treatment groups within the first 14 days to a similar extent.
During the follow-up of 6 months, percentages of patients with
recurrent stroke/transient ischemic attack were 11.0%, 5.9%,
9.7%, and 13.0% in the 4 groups, respectively. Overall mortality was
only 7.4%. Two parenchymal cerebral hematomas and 1 extracranial
bleeding episode occurred in treatment group 1 versus 1 and 0 in group
2, 2 and 0 in group 3, and 4 and 5 in group 4, respectively. During
certoparin treatment, 1 deep vein thrombosis but no pulmonary
embolism was observed.
Conclusions—Dose increase of certoparin up to 8000 U aXa twice daily did not improve the functional outcome of patients with ischemic stroke. Severe bleeding tended to be more frequent in the highest dose group only.
Key Words: heparin • stroke, acute • stroke, ischemic • stroke management • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  R Novakovic, G Toth, and P D Purdy Review of current and emerging therapies in acute ischemic stroke JNIS, July 1, 2009; 1(1): 13 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Paciaroni, G. Agnelli, S. Micheli, and V. Caso Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials Stroke, February 1, 2007; 38(2): 423 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Husemann, F. Muller, C. Krewer, S. Heller, and E. Koenig Effects of Locomotion Training With Assistance of a Robot-Driven Gait Orthosis in Hemiparetic Patients After Stroke: A Randomized Controlled Pilot Study Stroke, February 1, 2007; 38(2): 349 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J H McCabe and R D Rakhit Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. O'Donnell, E. Berge, and P. M. Sandset Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin? Stroke, February 1, 2006; 37(2): 452 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-C. Diener, E. B. Ringelstein, R. von Kummer, H. Landgraf, K. Koppenhagen, J. Harenberg, I. Rektor, A. Csanyi, D. Schneider, J. Klingelhofer, et al. Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial Stroke, January 1, 2006; 37(1): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Camerlingo, P. Salvi, G. Belloni, T. Gamba, B. M. Cesana, and A. Mamoli Intravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infarctions Stroke, November 1, 2005; 36(11): 2415 - 2420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M.W. Bath, L. Zhao, and S. Heptinstall Current status of stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C12 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Benatar Heparin use in acute ischaemic stroke: does evidence change practice? QJM, February 1, 2005; 98(2): 147 - 152. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association Circulation, September 9, 2003; 108(10): 1278 - 1290. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association Stroke, September 1, 2003; 34(9): 2310 - 2322. [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart, S. Palacio, and L. A. Pearce Atrial Fibrillation, Stroke, and Acute Antithrombotic Therapy: Analysis of Randomized Clinical Trials Stroke, November 1, 2002; 33(11): 2722 - 2727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick and W. Hacke Treatment of Acute Ischemic Stroke: Part II: Neuroprotection and Medical Management Circulation, September 24, 2002; 106(13): 1736 - 1740. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Coull, L. S. Williams, L. B. Goldstein, J. F. Meschia, D. Heitzman, S. Chaturvedi, K. C. Johnston, S. Starkman, L. B. Morgenstern, J. L. Wilterdink, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) Neurology, July 9, 2002; 59(1): 13 - 22. [Full Text] [PDF]
|
|
|
|
|
|
M. Moonis and M. Fisher Considering the Role of Heparin and Low-Molecular-Weight Heparins in Acute Ischemic Stroke Stroke, July 1, 2002; 33(7): 1927 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.M. Coull, L.S. Williams, L.B. Goldstein, J.F. Meschia, D. Heitzman, S. Chaturvedi, K.C. Johnston, S. Starkman, L.B. Morgenstern, J.L. Wilterdink, et al. Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) Stroke, July 1, 2002; 33(7): 1934 - 1942. [Full Text] [PDF]
|
|
|
|
|
|
A. Al-Sadat, M. Sunbulli, and S. Chaturvedi Use of Intravenous Heparin by North American Neurologists: Do the Data Matter? Stroke, June 1, 2002; 33(6): 1574 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke Stroke, March 1, 2002; 33(3): 856 - 861. [Abstract] [Full Text] [PDF]
|
|